Methylene Blue vs MK-2866
Well Studied vs Moderate Research
avoid Mechanism-based · 64% Both Methylene Blue and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Methylene Blue MK-2866
Weight 319.85 Da 389.33 Da
Half-life ~5-6 hours ~24 hours
Type Phenothiazine dye (C16H18ClN3S) Non-steroidal selective androgen receptor modulator (C19H14F3N3O3)
Key Benefits
Methylene Blue
01 Enhances mitochondrial respiration and ATP production by acting as an alternative electron carrier
02 Reduces mitochondrial reactive oxygen species generation
03 Supports memory consolidation and cognitive performance at low doses
04 Neuroprotective effects demonstrated in models of Alzheimer's, Parkinson's, and traumatic brain injury
05 Improves mitochondrial function in aging cells and tissues
06 FDA-approved treatment for acquired methemoglobinemia
07 Anti-inflammatory and antimicrobial properties
MK-2866
01 Increases lean body mass in a dose-dependent manner with clinical trial support
02 Preserves muscle mass during caloric deficit or catabolic conditions
03 Selective tissue activity reduces androgenic side effects compared to anabolic steroids
04 Oral bioavailability eliminates the need for injections
05 Does not aromatize to estrogen, avoiding gynecomastia and water retention
06 Improves physical function and stair-climbing power in clinical populations
07 Long 24-hour half-life allows convenient once-daily dosing
08 Mild side effect profile at commonly studied doses
Side Effects
Methylene Blue
Blue or blue-green discoloration of urine (expected and harmless)
Blue-green staining of the tongue and mouth with liquid formulations
Mild nausea or stomach discomfort, especially at higher doses
Blue discoloration of stool
Mild headache during initial use
MK-2866
Mild testosterone suppression (dose-dependent, typically 10-30% reduction at 25 mg)
HDL cholesterol reduction (10-20% suppression observed in clinical trials)
Headaches, particularly during the first 1-2 weeks
Mild back pain or muscle cramps
Transient fatigue toward the end of longer cycles
Slight reduction in libido at higher doses or extended cycle lengths
Contraindications
Concurrent use of SSRIs, SNRIs, or MAO inhibitors (serotonin syndrome risk)
Glucose-6-phosphate dehydrogenase (G6PD) deficiency (risk of severe hemolytic anemia)
Renal insufficiency (methylene blue is primarily renally excreted)
Known hypersensitivity to methylene blue or phenothiazine compounds
Pregnancy and breastfeeding (insufficient safety data)
Active liver disease or significantly elevated liver enzymes
Hormone-sensitive cancers (breast, prostate) without oncologist clearance
Pregnancy or breastfeeding (potential endocrine disruption to fetus/infant)
Individuals under 21 years of age (risk of premature HPTA disruption during development)
Concurrent use of hepatotoxic medications without liver function monitoring
Known hypersensitivity to MK-2866 or any formulation excipients
Competitive athletes subject to WADA or USADA anti-doping testing
Research Evidence
Methylene Blue MK-2866
Status Well Studied Moderate Research
References 5 studies 5 studies
Latest 2017 —
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.